Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology · 2025
Non-invasive peripheral nerve neuromodulation in diabetic neuropathic pain: A randomised controlled trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Genç Perdecioğlu Gevher Rabia, Yıldız Gökhan, Panpallı Ateş Mehlika, Yürük Damla, Akkaya Taylan
Аннотация
OBJECTIVES: Diabetic neuropathic pain (DNP) is one of the most common and challenging complications of diabetes mellitus and often results in significant distress and impaired quality of life. Pulsed radiofrequency (pRF) treatment has gained traction in recent years as an effective intervention for the management of chronic pain. Therefore, non-invasive pRF (NipRF) has been introduced as an innovative treatment that promises to provide pain relief without invasiveness. In this study, we aimed to evaluate the efficacy of NipRF in the treatment of DNP.
METHODS: This double-blind, randomized, controlled study included 64 patients with DNP and distal symmetric polyneuropathy refractory to multiple medical therapies, as confirmed by electroneuromyelography (ENMG). Participants were divided into two groups: one received NipRF treatment via a transcutaneous electrode (treatment group) and the other received a sham electrode (sham group) without radiofrequency. Pain levels were measured using the visual analog scale (VAS) and Self Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) before treatment and at 4 and 12 weeks after treatment.
RESULTS: The treatment group experienced significant reductions in the VAS and S-LANSS scores at 1 and 3 months post-treatment (p<0.001). The sham group showed a moderate, but not statistically significant, decrease at week 4, with scores reverting to baseline by week 12.
CONCLUSION: NipRF therapy may be a good option for DNP management. Its non-invasiveness and low risk of adverse events make it a good alternative to interventional and drug therapies.
METHODS: This double-blind, randomized, controlled study included 64 patients with DNP and distal symmetric polyneuropathy refractory to multiple medical therapies, as confirmed by electroneuromyelography (ENMG). Participants were divided into two groups: one received NipRF treatment via a transcutaneous electrode (treatment group) and the other received a sham electrode (sham group) without radiofrequency. Pain levels were measured using the visual analog scale (VAS) and Self Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) before treatment and at 4 and 12 weeks after treatment.
RESULTS: The treatment group experienced significant reductions in the VAS and S-LANSS scores at 1 and 3 months post-treatment (p<0.001). The sham group showed a moderate, but not statistically significant, decrease at week 4, with scores reverting to baseline by week 12.
CONCLUSION: NipRF therapy may be a good option for DNP management. Its non-invasiveness and low risk of adverse events make it a good alternative to interventional and drug therapies.